3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
13
Active not recruiting
2
Withdrawn
1
Terminated
1
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
72
Lung Neoplasms
34
Squamous Cell Carcinoma of Head and Neck
32
Head and Neck Neoplasms
30
Urinary Bladder Neoplasms
19
Uterine Cervical Neoplasms
18
Stomach Neoplasms
17
Esophageal Neoplasms
17
Small Cell Lung Carcinoma
16
Cholangiocarcinoma
16
Neoplasm Metastasis
13
Ovarian Neoplasms
12
Carcinoma, Squamous Cell
11
Breast Neoplasms
11
Neoplasms
10
Mesothelioma, Malignant
9
Esophageal Squamous Cell Carcinoma
8
Biliary Tract Neoplasms
8
Sarcoma
7
Fallopian Tube Neoplasms
7
Pancreatic Neoplasms
6
Mesothelioma
6
Adenocarcinoma of Lung
6
Adenocarcinoma Of Esophagus
6
Recurrence
5
Gallbladder Neoplasms
5
Carcinoma, Ovarian Epithelial
5
Bile Duct Neoplasms
5
Triple Negative Breast Neoplasms
4
Osteosarcoma
4
Interventions
Gemcitabine
2
rucaparib
1
romidepsin
1
pembrolizumab
1
enfortumab vedotin
1
Trastuzumab
1
Standard of Care
1
Sorafenib
1
Paclitaxel
1
Depsipeptides
1
Crizotinib
1
Cisplatin
1
Carboplatin
1
Afatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Urethral Neoplasms
×
Cisplatin
×
Clear all
NCT03288545
2026-03-24
EV-103
Astellas Pharma Inc
Phase 1/2
Terminated
348 enrolled
1 FDA